US Patent

US8771648 — (Trimethoxyphenylamino) pyrimidinyl formulations

Formulation · Assigned to Rigel Pharmaceuticals Inc · Expires 2032-07-27 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions containing a compound of Formula (I) and one or more effervescent agents, along with other ingredients.

USPTO Abstract

There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Drugs covered by this patent

Patent Metadata

Patent number
US8771648
Jurisdiction
US
Classification
Formulation
Expires
2032-07-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.